In 29 HCC patients treated with Sorafenib from TCGA-LIHC cohort, patients with low expression of HNRNPC, IGF2BP1, METTL3 and YTHDF1, namely high m6A score, had a better overall survival (Fig. 7E). Here, METTL3 is linked to hepatocellular carcinoma.